BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20615823)

  • 1. Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.
    Homet Moreno B; Garralda Cabanas E; Hitt R
    Clin Transl Oncol; 2010 Jul; 12(7):468-72. PubMed ID: 20615823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in therapy for gastrointestinal stromal tumors.
    Maki RG
    Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
    Pilotte AP
    Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
    George S
    Curr Oncol Rep; 2007 Jul; 9(4):323-7. PubMed ID: 17588358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
    Mahmood ST; Agresta S; Vigil CE; Zhao X; Han G; D'Amato G; Calitri CE; Dean M; Garrett C; Schell MJ; Antonia S; Chiappori A
    Int J Cancer; 2011 Oct; 129(8):1963-9. PubMed ID: 21154746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for the treatment of soft tissue sarcomas.
    Cassier PA; Dufresne A; Fayette J; Alberti L; Ranchere D; Ray-Coquard I; Blay JY
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):139-53. PubMed ID: 17355219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
    Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
    Schöffski P; Bukowski R; Flodgren P; Ravaud A
    Ann Oncol; 2009 May; 20 Suppl 1():i25-i30. PubMed ID: 19430005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?
    von Mehren M; Watson JC
    Oncology (Williston Park); 2009 Jan; 23(1):65-6. PubMed ID: 19283923
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel approaches to imatinib- and sunitinib-resistant GIST.
    Reichardt P
    Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
    Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal stromal tumors: imatinib and beyond.
    Schnadig ID; Blanke CD
    Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib in the management of gastrointestinal stromal tumours (GISTs).
    Hopkins TG; Marples M; Stark D
    Eur J Surg Oncol; 2008 Aug; 34(8):844-850. PubMed ID: 18082353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
    Montemurro M; Bauer S
    Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.